DRTX Insider Trading Activity and SEC Form 4 Filings
DRTX insider trading summary
No open-market insider purchases or sales of Durata Therapeutics, Inc. (DRTX) have been reported on SEC Form 4 in the past 12 months.
Latest DRTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 12, 2014 | John Patrick Shannon Jr | Chief Commercial Officer | Buy | $41K (3,000 @ $13.72) |
| Jun 12, 2014 | Paul R Edick | Chief Executive Officer | Buy | $46K (3,000 @ $15.23) |
| May 12, 2014 | Schutter Richard U De | Director | Buy | $234K (15,000 @ $15.57) |
| Mar 21, 2014 | Aisling Capital III LP | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 21, 2014 | Steve Elms | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 21, 2014 | Aisling Capital Partners III LLC | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 21, 2014 | Dennis J Purcell | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 21, 2014 | Aisling Capital Partners III LP | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 21, 2014 | Andrew N Schiff | 10% Owner | Sell | $41K (2,649 @ $15.57) |
| Mar 20, 2014 | Steve Elms | 10% Owner | Sell | $1.5M (98,000 @ $15.74) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.